Why this peptide is on people's radar
VIP has two distinct paths into the peptide conversation. The first is academic-and-pharmaceutical: VIP and its synthetic derivatives have been studied in sarcoidosis, pulmonary hypertension, and related inflammatory pulmonary conditions. Aviptadil (a synthetic VIP) was investigated through Phase 2 / Phase 3 trials and received FDA Emergency Use Authorization briefly during COVID-19 for severe respiratory failure (which was subsequently withdrawn after the EUA window closed). VIP's natural anti-inflammatory and vasodilator biology is well-characterized.
The second path is the chronic-inflammatory-illness route, particularly through the work of Ritchie Shoemaker and his "Chronic Inflammatory Response Syndrome" (CIRS) framework around mold and biotoxin illness. In Shoemaker-protocol practice, intranasal VIP is added late in treatment for patients whose inflammatory markers haven't normalized after other interventions. The framework has a passionate practitioner community and many anecdotal reports of benefit; rigorous published clinical-trial evidence specifically supporting the protocol use case is much thinner than the practitioner literature suggests.
The honest framing: VIP's underlying biology is real, the academic research in sarcoidosis is real, and the CIRS use case rests on a much thinner evidence base. Patients with chronic inflammatory or environmental-illness symptoms severe enough to consider VIP should be working with clinicians experienced in their specific condition, not relying on internet research-peptide protocols.
What people are usually trying to do with it
People exploring VIP are usually focused on:
- Chronic inflammatory illness in CIRS/mold-illness frameworks
- Sarcoidosis-related symptoms
- Persistent post-viral inflammation
- Anti-inflammatory support after other interventions haven't normalized things
- Cognitive or fatigue symptoms attributed to chronic inflammation
What the science actually shows
Plain-English summary:
Anti-inflammatory and immunomodulatory biology
VIP's natural anti-inflammatory effects are well-characterized. Activates VPAC1 and VPAC2 receptors on immune and other tissues, promoting Th2-type immune responses and suppressing inflammatory cytokines.
Sarcoidosis (clinical research)
Trials of inhaled VIP in sarcoidosis have shown reductions in inflammatory markers and improvements in lung function. Not FDA-approved for this indication.
Aviptadil and COVID-19 history
Synthetic VIP (aviptadil) had a brief FDA Emergency Use Authorization during COVID-19 for severe respiratory failure. The EUA expired with the broader EUA framework; aviptadil never converted to standard approval.
CIRS protocol use
Intranasal VIP in Shoemaker-protocol practice is supported by clinician case reports and anecdotal evidence rather than rigorous published clinical trials. Some retrospective and observational studies exist within the practitioner community.
What hasn't been demonstrated
FDA-approved indication. Rigorous Western randomized-trial evidence for the CIRS-protocol use case. Long-term safety with chronic intranasal use.
The honest read
What's solid:
VIP's natural anti-inflammatory biology is well-characterized. The pulmonary and sarcoidosis research is meaningful. The aviptadil COVID-19 EUA, while it didn't convert to lasting approval, reflected real trial signals.
What's still unproven:
Most of the chronic-inflammatory-illness use case. The CIRS framework is contested; rigorous clinical evidence for VIP specifically within CIRS is thin. Anyone with chronic symptoms severe enough to consider VIP should ensure they have proper differential-diagnosis evaluation from clinicians experienced in their specific condition.
What's hyped beyond the evidence:
VIP as a general "fix everything inflammatory" peptide. The clinical evidence is in defined research contexts (sarcoidosis, severe respiratory failure). Translation to chronic-fatigue / mold-illness / general inflammatory wellness contexts rests on practitioner experience and anecdote rather than rigorous trials.
Things to know if you're looking into it
- How it's used in research-peptide contexts: typically a compounded intranasal spray. Some research uses inhaled or IV forms.
- Regulatory status: not FDA-approved. Not currently on the FDA Category 2 list as of 2026.
- Common in CIRS protocols: intranasal VIP is a recurring component of Shoemaker-protocol practice. The framework is contested in mainstream medicine.
- Reported tolerability: generally favorable in published research and community use. Short half-life means the systemic-exposure picture is limited.
- Healthcare provider involvement: appropriate, especially for anyone with chronic symptoms warranting proper diagnostic evaluation.
- Specific dosing protocols, mechanism, and the full reference list: all in the "Want to go deeper?" section below.
What people often ask
Is VIP FDA-approved?
No. Aviptadil (a synthetic VIP) had a brief FDA Emergency Use Authorization during COVID-19 that expired with the broader EUA framework. No standing FDA approval for any indication.
Will it help my mold illness or CIRS symptoms?
The CIRS framework treats chronic inflammatory illness and is contested in mainstream medicine. VIP's role within that framework rests on practitioner experience and anecdotal evidence rather than rigorous published trials. Anyone with chronic complex symptoms should ensure they have thorough differential diagnosis from clinicians experienced in their condition.
Does it help sarcoidosis?
Inhaled VIP has shown signals in sarcoidosis trials. Not FDA-approved for this indication. People with sarcoidosis should be working with pulmonology specialists.
Are there side effects?
Reported side effects in research-community use are generally mild and uncommon, possible nasal irritation with intranasal use, occasional flushing. Long-term safety hasn't been well-characterized.
FDA and regulatory status
Status as of May 5, 2026: Not FDA-approved. The aviptadil EUA for severe COVID-19 respiratory failure has expired. Not currently on the FDA Category 2 list. Status updates land here when they happen.
Want to go deeper?
Mechanism, dosing, and references.
Background
VIP is a 28-amino-acid neuropeptide from the secretin/glucagon family. Originally isolated from porcine intestine in 1970 by Sami Said. Distributed widely throughout the body, central and peripheral nervous system, gastrointestinal tract, immune system, and lungs.
Mechanism of action
VIP binds VPAC1 and VPAC2 G-protein-coupled receptors on immune cells, smooth muscle, and other tissues. Effects include vasodilation, smooth-muscle relaxation, anti-inflammatory signaling (suppression of pro-inflammatory cytokines, support of regulatory T-cell development), and modulation of innate immunity.
Research-community dosing
Intranasal: typically 50 mcg per nostril, 2-4x daily, in CIRS protocols. Inhaled: 100-200 mcg per session in published sarcoidosis research.
References
- Delgado M, Pozo D, Ganea D. (2004). "The significance of vasoactive intestinal peptide in immunomodulation." Pharmacol Rev, 56(2), 249–290. PubMed
- Prasse A, Zissel G, Lützen N, et al. (2010). "Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis." Am J Respir Crit Care Med, 182(4), 540–548. PubMed
- Said SI, Mutt V. (1970). "Polypeptide with broad biological activity: isolation from small intestine." Science, 169(3951), 1217–1218. PubMed